Kymera Therapeutics To Announce Results From Its Phase 1 Clinical Trial Evaluating Single And Multiple-Ascending Doses Of KT-579 In Healthy Volunteers On October 29

Benzinga · 4d ago

Announcement as part of its previously scheduled third quarter 2026 financial results. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.